Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt N/A
JNJ's Cash-to-Debt is ranked lower than
59% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. JNJ: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.19 Max: N/A
Current: N/A
Equity-to-Asset 0.50
JNJ's Equity-to-Asset is ranked lower than
69% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. JNJ: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.53 Max: 0.66
Current: 0.5
0.44
0.66
Interest Coverage 32.77
JNJ's Interest Coverage is ranked lower than
62% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. JNJ: 32.77 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 46.15
Current: 32.77
28.29
46.15
Piotroski F-Score: 8
Altman Z-Score: 5.28
Beneish M-Score: -2.48
WACC vs ROIC
5.95%
31.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 29.47
JNJ's Operating Margin % is ranked higher than
92% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. JNJ: 29.47 )
Ranked among companies with meaningful Operating Margin % only.
JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 22.36  Med: 25.94 Max: 29.47
Current: 29.47
22.36
29.47
Net Margin % 22.87
JNJ's Net Margin % is ranked higher than
89% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. JNJ: 22.87 )
Ranked among companies with meaningful Net Margin % only.
JNJ' s Net Margin % Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 23.01
Current: 22.87
14.87
23.01
ROE % 22.96
JNJ's ROE % is ranked higher than
86% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. JNJ: 22.96 )
Ranked among companies with meaningful ROE % only.
JNJ' s ROE % Range Over the Past 10 Years
Min: 17.02  Med: 23.04 Max: 30.17
Current: 22.96
17.02
30.17
ROA % 11.94
JNJ's ROA % is ranked higher than
83% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. JNJ: 11.94 )
Ranked among companies with meaningful ROA % only.
JNJ' s ROA % Range Over the Past 10 Years
Min: 8.93  Med: 12.23 Max: 15.61
Current: 11.94
8.93
15.61
ROC (Joel Greenblatt) % 110.70
JNJ's ROC (Joel Greenblatt) % is ranked higher than
94% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. JNJ: 110.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 119.25
Current: 110.7
65.66
119.25
3-Year Revenue Growth Rate 1.30
JNJ's 3-Year Revenue Growth Rate is ranked lower than
66% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. JNJ: 1.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 9.3 Max: 14.8
Current: 1.3
1.3
14.8
3-Year EBITDA Growth Rate 7.70
JNJ's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. JNJ: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 11.5 Max: 24.1
Current: 7.7
-6.6
24.1
3-Year EPS without NRI Growth Rate 7.20
JNJ's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. JNJ: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 12.4 Max: 34.2
Current: 7.2
-8.6
34.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: 2017-07-19 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

JNJ Guru Trades in Q2 2016

Ray Dalio 129,700 sh (New)
Tom Russo 2,050 sh (New)
Louis Moore Bacon 3,552 sh (New)
Lee Ainslie 28,230 sh (New)
John Paulson 128,000 sh (New)
Jim Chanos 49,843 sh (+67.65%)
RS Investment Management 10,007 sh (+19.17%)
Jeremy Grantham 9,741,420 sh (+7.80%)
Diamond Hill Capital 2,110 sh (+7.16%)
Dodge & Cox 35,185 sh (+1.08%)
John Rogers 857,563 sh (+0.78%)
John Buckingham 63,881 sh (+0.38%)
Mairs and Power 2,185,819 sh (+0.03%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
John Hussman 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
David Rolfe 5,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Chuck Royce Sold Out
John Burbank Sold Out
Jeff Auxier 105,126 sh (-0.05%)
Ken Fisher 10,845,150 sh (-0.08%)
Murray Stahl 30,622 sh (-0.49%)
Richard Snow 3,220 sh (-1.23%)
Paul Tudor Jones 15,553 sh (-2.03%)
Tweedy Browne 3,216,513 sh (-4.93%)
Donald Yacktman 6,671,349 sh (-5.78%)
PRIMECAP Management 2,830,937 sh (-6.37%)
Manning & Napier Advisors, Inc 3,297,804 sh (-6.93%)
Richard Pzena 1,103,032 sh (-6.94%)
Ruane Cunniff 12,933 sh (-7.12%)
Mario Gabelli 312,831 sh (-7.33%)
Charles Brandes 133,128 sh (-8.97%)
Pioneer Investments 3,223,857 sh (-12.28%)
Barrow, Hanley, Mewhinney & Strauss 13,210,591 sh (-13.81%)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
Robert Olstein 41,000 sh (-18.00%)
First Eagle Investment 759,790 sh (-33.52%)
Sarah Ketterer 787,234 sh (-42.30%)
Jim Simons 626,100 sh (-73.70%)
Joel Greenblatt 4,906 sh (-97.97%)
» More
Q3 2016

JNJ Guru Trades in Q3 2016

Eaton Vance Worldwide Health Sciences Fund 450,936 sh (New)
Joel Greenblatt 214,043 sh (+4262.88%)
Jim Simons 1,475,100 sh (+135.60%)
Paul Tudor Jones 28,124 sh (+80.83%)
Diamond Hill Capital 2,296 sh (+8.82%)
Pioneer Investments 3,454,669 sh (+7.16%)
John Rogers 858,549 sh (+0.11%)
Tweedy Browne Global Value 865,835 sh (unchged)
John Hussman 25,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Ken Fisher 10,845,620 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,250 sh (unchged)
Richard Perry Sold Out
Tom Russo Sold Out
Richard Snow 3,215 sh (-0.16%)
Dodge & Cox 34,985 sh (-0.57%)
T Rowe Price Equity Income Fund 3,380,000 sh (-0.59%)
Jeff Auxier 104,176 sh (-0.90%)
Mairs and Power 2,153,237 sh (-1.49%)
John Buckingham 62,429 sh (-2.27%)
Charles Brandes 126,627 sh (-4.88%)
Mario Gabelli 294,127 sh (-5.98%)
Murray Stahl 28,648 sh (-6.45%)
Barrow, Hanley, Mewhinney & Strauss 12,334,416 sh (-6.63%)
Lee Ainslie 26,320 sh (-6.77%)
Tweedy Browne 2,978,783 sh (-7.39%)
Yacktman Focused Fund 1,800,000 sh (-7.69%)
Donald Yacktman 6,143,753 sh (-7.91%)
Manning & Napier Advisors, Inc 3,028,532 sh (-8.17%)
Richard Pzena 1,002,314 sh (-9.13%)
Sarah Ketterer 705,335 sh (-10.40%)
PRIMECAP Management 2,519,397 sh (-11.00%)
Yacktman Fund 3,200,000 sh (-11.11%)
Louis Moore Bacon 2,875 sh (-19.06%)
Michael Price 20,000 sh (-20.00%)
Jeremy Grantham 7,282,964 sh (-25.24%)
Robert Olstein 30,000 sh (-26.83%)
Jim Chanos 35,387 sh (-29.00%)
Ruane Cunniff 5,713 sh (-55.83%)
Ray Dalio 44,400 sh (-65.77%)
John Paulson 35,000 sh (-72.66%)
First Eagle Investment 28,177 sh (-96.29%)
» More
Q4 2016

JNJ Guru Trades in Q4 2016

Steven Cohen 245,700 sh (New)
Jim Simons 3,423,100 sh (+132.06%)
Joel Greenblatt 475,722 sh (+122.26%)
Prem Watsa 151,250 sh (+82.56%)
Pioneer Investments 4,830,327 sh (+39.82%)
Sarah Ketterer 769,679 sh (+9.12%)
Lee Ainslie 28,530 sh (+8.40%)
Charles Brandes 131,352 sh (+3.73%)
John Rogers 870,359 sh (+1.38%)
Diamond Hill Capital 2,327 sh (+1.35%)
Ken Fisher 10,957,134 sh (+1.03%)
John Buckingham 62,716 sh (+0.46%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Yacktman Focused Fund 1,800,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Michael Price 20,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,250 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 450,936 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Jim Chanos Sold Out
John Paulson Sold Out
Jeff Auxier 104,076 sh (-0.10%)
T Rowe Price Equity Income Fund 3,370,000 sh (-0.30%)
Richard Pzena 998,964 sh (-0.33%)
Mairs and Power 2,143,539 sh (-0.45%)
First Eagle Investment 28,031 sh (-0.52%)
Donald Yacktman 6,035,969 sh (-1.75%)
Dodge & Cox 34,185 sh (-2.29%)
Manning & Napier Advisors, Inc 2,942,895 sh (-2.83%)
Robert Olstein 29,000 sh (-3.33%)
Barrow, Hanley, Mewhinney & Strauss 11,875,386 sh (-3.72%)
Murray Stahl 26,905 sh (-6.08%)
Ruane Cunniff 5,238 sh (-8.31%)
Mario Gabelli 257,586 sh (-12.42%)
PRIMECAP Management 2,171,097 sh (-13.82%)
Tweedy Browne 2,386,562 sh (-19.88%)
Jeremy Grantham 5,255,334 sh (-27.84%)
Paul Tudor Jones 5,800 sh (-79.38%)
» More
Q1 2017

JNJ Guru Trades in Q1 2017

T Rowe Price Equity Income Fund 3,500,000 sh (+3.86%)
Ken Fisher 11,093,898 sh (+1.25%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Yacktman Focused Fund 1,700,000 sh (-5.56%)
Manning & Napier Advisors, Inc 1,933,205 sh (-34.31%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:RHHBY, NYSE:PFE, OTCPK:NVSEF, NYSE:MRK, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:LLY, NYSE:BMY, NYSE:AZN, OTCPK:SZUKF, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHF » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the company: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. About half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Top Ranked Articles about Johnson & Johnson

Johnson & Johnson Beats on Profit, Misses on Sales in 1st Quarter Shares were down in early afternoon trading
Health care giant Johnson & Johnson (NYSE:JNJ) posted sluggish sales for the first quarter of the year, offsetting an increase in profit. Sales were squeezed by pressure to reduce drug prices and a global decline in sales of health products. Read more...
The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction Can the inverse relationship between stock valuations and interest rates be relied upon?
Introduction Read more...
Case Study: Insider Ownership Among Dividend Kings Analyzing the ownership of 5 company's CEOs
(Published by Nicholas McCullum on March 14) Read more...
6 Signs of a Shareholder-Friendly Stock Traits to look for when evaluating a company
(Published March 13 by Nicholas McCullum) Read more...
Results of Johnson & Johnson's Psoriasis Clinical Trials Impressive Patients treated with guselkumab achieved meaningful improvement in skin clearance and other disease activity measures
Janssen Research & Development LLC, part of Johnson & Johnson (NYSE:JNJ) Pharmaceutical Research and Development, reported last March 3 through the PRNewswire the results from two Phase 3 clinical trials, VOYAGE 2 and NAVIGATE. Read more...
5 Companies Hit 52-Week Highs Johnson & Johnson, Reynolds American, Aon PLC, Danaher, Amazon reach milestones
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Isaly, the only manager to beat the market for 25 consecutive years, talks about pressing issues in the sector
Samuel Isaly is one of the foremost health care investors in the U.S. He founded OrbiMed Advisors, a global management firm with $13 billion in assets that invests across biotech, pharmaceuticals, medical devices, digital innovations and other areas of the industry. In January 2016, Barron’s Magazine recognized him as the only U.S. mutual fund manager to beat the S&P 500 for 25 consecutive years ending Nov. 30, 2015. Read more...
Why Shareholders Care About Dividends A 3% yield may not sound exciting, but there are many good reasons why investors care about dividends
(Published Jan. 27 by The Financial Canadian) Read more...
The Difference Between the Ex-Dividend Date, Record Date and Pay Date Clearing up confusion and common misconceptions about the dividend payment process
(Published Jan. 23 by The Financial Canadian) Read more...
Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...

Ratios

vs
industry
vs
history
PE Ratio 20.76
JNJ's PE Ratio is ranked higher than
67% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. JNJ: 20.76 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 17.74 Max: 24
Current: 20.76
10.5
24
Forward PE Ratio 17.39
JNJ's Forward PE Ratio is ranked lower than
66% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. JNJ: 17.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.76
JNJ's PE Ratio without NRI is ranked higher than
67% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. JNJ: 20.76 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 17.74 Max: 24
Current: 20.76
10.5
24
Price-to-Owner-Earnings 23.09
JNJ's Price-to-Owner-Earnings is ranked higher than
66% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. JNJ: 23.09 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.5 Max: 25.26
Current: 23.09
10.19
25.26
PB Ratio 4.76
JNJ's PB Ratio is ranked lower than
71% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. JNJ: 4.76 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 4.99
Current: 4.76
2.68
4.99
PS Ratio 4.78
JNJ's PS Ratio is ranked lower than
66% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. JNJ: 4.78 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.97
Current: 4.78
2.17
4.97
Price-to-Free-Cash-Flow 22.17
JNJ's Price-to-Free-Cash-Flow is ranked higher than
53% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. JNJ: 22.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.28  Med: 16.53 Max: 24.36
Current: 22.17
10.28
24.36
Price-to-Operating-Cash-Flow 18.36
JNJ's Price-to-Operating-Cash-Flow is ranked lower than
54% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. JNJ: 18.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.98  Med: 13.2 Max: 19.53
Current: 18.36
8.98
19.53
EV-to-EBIT 15.60
JNJ's EV-to-EBIT is ranked higher than
67% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. JNJ: 15.60 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13 Max: 18.2
Current: 15.6
7.8
18.2
EV-to-EBITDA 13.70
JNJ's EV-to-EBITDA is ranked higher than
64% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. JNJ: 13.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11 Max: 14.8
Current: 13.7
6.7
14.8
PEG Ratio 2.31
JNJ's PEG Ratio is ranked lower than
57% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.90 vs. JNJ: 2.31 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.81 Max: 25.96
Current: 2.31
1.21
25.96
Shiller PE Ratio 24.62
JNJ's Shiller PE Ratio is ranked higher than
76% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. JNJ: 24.62 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.52  Med: 21.27 Max: 29.58
Current: 24.62
15.52
29.58
Current Ratio 2.47
JNJ's Current Ratio is ranked lower than
52% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. JNJ: 2.47 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.85 Max: 2.49
Current: 2.47
1.2
2.49
Quick Ratio 2.16
JNJ's Quick Ratio is ranked higher than
55% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. JNJ: 2.16 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.4 Max: 2.18
Current: 2.16
0.94
2.18
Days Inventory 138.93
JNJ's Days Inventory is ranked lower than
62% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. JNJ: 138.93 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 110.33 Max: 138.93
Current: 138.93
100.19
138.93
Days Sales Outstanding 59.16
JNJ's Days Sales Outstanding is ranked higher than
64% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. JNJ: 59.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 59.16
53.94
61.4
Days Payable 116.14
JNJ's Days Payable is ranked higher than
75% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. JNJ: 116.14 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 116.14
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.59
JNJ's Dividend Yield % is ranked higher than
73% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. JNJ: 2.59 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.05  Med: 2.84 Max: 3.84
Current: 2.59
2.05
3.84
Dividend Payout Ratio 0.53
JNJ's Dividend Payout Ratio is ranked lower than
70% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. JNJ: 0.53 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.51 Max: 0.65
Current: 0.53
0.39
0.65
3-Year Dividend Growth Rate 6.70
JNJ's 3-Year Dividend Growth Rate is ranked lower than
54% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 6.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.7  Med: 13.4 Max: 17.5
Current: 6.7
6.7
17.5
Forward Dividend Yield % 2.59
JNJ's Forward Dividend Yield % is ranked higher than
71% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. JNJ: 2.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.63
JNJ's 5-Year Yield-on-Cost % is ranked higher than
72% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. JNJ: 3.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.88  Med: 3.98 Max: 5.39
Current: 3.63
2.88
5.39
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.1 Max: 2.3
Current: 1.2
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.20
JNJ's Price-to-Tangible-Book is ranked lower than
90% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. JNJ: 16.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
JNJ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.5  Med: 9.59 Max: 17.97
Current: 16.2
4.5
17.97
Price-to-Intrinsic-Value-Projected-FCF 1.75
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
63% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. JNJ: 1.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.63 Max: 3.43
Current: 1.75
0.98
3.43
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.94
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
75% of the 80 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. JNJ: 1.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.48
JNJ's Price-to-Median-PS-Value is ranked lower than
71% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. JNJ: 1.48 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.98 Max: 1.76
Current: 1.48
0.5
1.76
Price-to-Peter-Lynch-Fair-Value 2.13
JNJ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
66% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. JNJ: 2.13 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JNJ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.27  Med: 1.91 Max: 3.81
Current: 2.13
1.27
3.81
Price-to-Graham-Number 3.89
JNJ's Price-to-Graham-Number is ranked lower than
75% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. JNJ: 3.89 )
Ranked among companies with meaningful Price-to-Graham-Number only.
JNJ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.75  Med: 3.09 Max: 5.43
Current: 3.89
1.75
5.43
Earnings Yield (Greenblatt) % 6.43
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. JNJ: 6.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.5  Med: 7.7 Max: 12.9
Current: 6.43
5.5
12.9
Forward Rate of Return (Yacktman) % 13.96
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. JNJ: 13.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.8  Med: 13.8 Max: 18.2
Current: 13.96
1.8
18.2

More Statistics

Revenue (TTM) (Mil) $72,174
EPS (TTM) $ 5.95
Beta0.64
Short Percentage of Float0.64%
52-Week Range $109.32 - 129.00
Shares Outstanding (Mil)2,710.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 75,352 78,234 82,700
EPS ($) 7.10 7.56 8.05
EPS without NRI ($) 7.10 7.56 8.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.71%
Dividends per Share ($) 3.35 3.55 3.78
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
Johnson & Johnson Announces Dividend Increase of 5.0% Apr 27 2017 
Johnson & Johnson to Host Pharmaceutical Business Review Apr 24 2017 
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity Apr 21 2017 
Johnson & Johnson Beats on Profit, Misses on Sales in 1st Quarter Apr 19 2017 
Study These Gurus, but Don’t Buy Their Funds Apr 14 2017 
Recession-Resistant Total Return Stock in the Packaged Foods Industry Apr 11 2017 
Johnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer S Mar 31 2017 
The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction Mar 24 2017 
4 Biotech Stocks to Watch Mar 22 2017 
What You Need to Know About the March Rate Hike Mar 20 2017 

More From Other Websites
[$$] Sanofi 1Q Net Profit Rises on Sale of Animal-Health Unit Apr 28 2017
Is Remicade Losing Out to Biosimilars? Apr 28 2017
Global med-tech firms, India locked in tussle after stent price sting Apr 28 2017
This Medtech Stock Crashed Below 3 Technical Levels; Can It Get Up? Apr 27 2017
AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Apr 27 2017
Johnson & Johnson to increase quarterly dividend by 5% from 80 cents per share to 84 cents Apr 27 2017
Wait for This Correction in Johnson & Johnson to End Apr 27 2017
Johnson & Johnson Announces Dividend Increase of 5.0% Apr 27 2017
What's Happening With Johnson & Johnson's Pharmaceuticals Business? Apr 27 2017
Stroke drug Xarelto, plastics lift Bayer earnings Apr 27 2017
Johnson & Johnson's Medical Device Business: What Investors Need to Know Apr 26 2017
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, Honeywell, Alphabet and SunTrust... Apr 26 2017
Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment Apr 26 2017
How ZBH Stock Has Performed Recently Apr 26 2017
Top Research Reports for Today: JNJ, SLB, HOM Apr 25 2017
Here's Why Risk-Averse Investors May Want to Think Twice About Buying Johnson & Johnson Apr 25 2017
Why Achillion Pharmaceuticals Stock Sank on Monday Apr 25 2017
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Apr 25 2017
Morning News Call - India, April 25 Apr 24 2017
3 Top Consumer Staples Stocks to Buy in 2017 Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)